97 related articles for article (PubMed ID: 2908626)
1. Antibody-toxin conjugation.
Marsh JW; Srinivasachar K; Neville DM
Cancer Treat Res; 1988; 37():213-37. PubMed ID: 2908626
[No Abstract] [Full Text] [Related]
2. Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins.
Wawrzynczak EJ; Thorpe PE
Cancer Treat Res; 1988; 37():239-51. PubMed ID: 2908627
[No Abstract] [Full Text] [Related]
3. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
[TBL] [Abstract][Full Text] [Related]
4. Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents.
Lau A; Bérubé G; Ford CH
Bioorg Med Chem; 1995 Oct; 3(10):1299-304. PubMed ID: 8564395
[TBL] [Abstract][Full Text] [Related]
5. A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates.
Zara JJ; Wood RD; Boon P; Kim CH; Pomato N; Bredehorst R; Vogel CW
Anal Biochem; 1991 Apr; 194(1):156-62. PubMed ID: 1867379
[TBL] [Abstract][Full Text] [Related]
6. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
[TBL] [Abstract][Full Text] [Related]
7. Oriented and covalent immobilization of target molecules to solid supports: synthesis and application of a light-activatable and thiol-reactive cross-linking reagent.
Collioud A; Clémence JF; Sänger M; Sigrist H
Bioconjug Chem; 1993; 4(6):528-36. PubMed ID: 7508269
[TBL] [Abstract][Full Text] [Related]
8. Preparation of cytotoxic antibody-toxin conjugates.
Cumber AJ; Wawrzynczak EJ
Methods Mol Biol; 1998; 80():135-44. PubMed ID: 9664370
[No Abstract] [Full Text] [Related]
9. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.
Wakankar AA; Feeney MB; Rivera J; Chen Y; Kim M; Sharma VK; Wang YJ
Bioconjug Chem; 2010 Sep; 21(9):1588-95. PubMed ID: 20698491
[TBL] [Abstract][Full Text] [Related]
11. Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies.
Alonso CM; Palumbo A; Bullous AJ; Pretto F; Neri D; Boyle RW
Bioconjug Chem; 2010 Feb; 21(2):302-13. PubMed ID: 20073477
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma.
Rosenblum M
Adv Pharmacol; 2004; 51():209-28. PubMed ID: 15464911
[No Abstract] [Full Text] [Related]
13. A new 'solid phase' procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates).
Dosio F; Brusa P; Delprino L; Ceruti M; Grosa G; Cattel L; Bolognesi A; Barbieri L
Farmaco; 1993 Jan; 48(1):105-15. PubMed ID: 8457275
[TBL] [Abstract][Full Text] [Related]
14. Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin.
Avila AD; Calderón CF; Pérez RM; Pons C; Pereda CM; Ortiz AR
Biol Res; 2007; 40(2):173-83. PubMed ID: 18064354
[TBL] [Abstract][Full Text] [Related]
15. Preparation and photoactivation of caged fluorophores and caged proteins using a new class of heterobifunctional, photocleavable cross-linking reagents.
Ottl J; Gabriel D; Marriott G
Bioconjug Chem; 1998; 9(2):143-51. PubMed ID: 9548528
[TBL] [Abstract][Full Text] [Related]
16. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
Arpicco S; Dosio F; Brusa P; Crosasso P; Cattel L
Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838
[TBL] [Abstract][Full Text] [Related]
17. Rational design of immunotoxins: current progress and future prospects.
Wawrzynczak EJ
Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633
[TBL] [Abstract][Full Text] [Related]
18. N-terminal modification of immunoglobulin polypeptide chains tagged with isothiocyanato chelates.
Rana TM; Meares CF
Bioconjug Chem; 1990; 1(5):357-62. PubMed ID: 2129106
[TBL] [Abstract][Full Text] [Related]
19. Bifunctional reagents.
Ji TH
Methods Enzymol; 1983; 91():580-609. PubMed ID: 6855603
[No Abstract] [Full Text] [Related]
20. Immunotoxins containing single-chain ribosome-inactivating proteins.
Lambert JM; Blättler WA; McIntyre GD; Goldmacher VS; Scott CF
Cancer Treat Res; 1988; 37():175-209. PubMed ID: 2908625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
